Research Radartracking 2 published studies · 1 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Vitamin D₃ + K₂

D3+K2 combo: VDR/MGP ↑, bone resorption ↓; emerging in breast/prostate/liver/bladder.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Emerging Clinical — Supportive observational data and small trials; consistent mechanistic synergy in preclinical models.Cholecalciferol + MenaquinoneD3 + MK-7

Forms: Combined capsules (2000-5000 IU D3 + 100-200 mcg K2 MK-7) · Separate drops (D3 oil + K2 softgel)

Educational only, not medical advice. OncoForge makes no claim that Vitamin D₃ + K₂ treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

D₃ supports VDR-driven differentiation and immune tone while increasing calcium absorption; K₂ activates matrix Gla protein (MGP) and osteocalcin to prevent ectopic calcification and favor skeletal deposition. Together they improve calcium routing and may add antiproliferative/autophagic pressure in some tumors.

Evidence at a glance

Tier 2 · animalBreastProstateLiverBladder

Observational VDR/MGP synergy; phase II prostate PSA; bone meta modest; ongoing breast/liver trials; MK-7 edges K1 in extrahepatic.

How it may work

D₃ (cholecalciferol → calcitriol) activates VDR to induce cell-cycle arrest, apoptosis, and immune modulation. K₂ (MK-7/MK-4) provides γ-carboxylation of MGP/osteocalcin, reducing vascular/soft-tissue calcification and supporting bone health; K₂ also induces autophagy/apoptosis in tumor models and may suppress metastasis.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

  • Calcium Routing↑Vascular to skeletal deposition
  • VDR↑Differentiation and immune modulation
  • MGP Carboxylation↑Anti-calcification activation
  • Bone Resorption↓RANKL axis suppression
  • Apoptosis↑Autophagy and cell death induction
Calcium RoutingVDRMGP CarboxylationBone Resorption

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Overlapping mechanisms

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories
HypercalcemiaGi UpsetKidney Stones
Potential interactions
  • warfarinContraindicateHighTheoreticalK2 antagonizes vitamin K antagonists.
  • calcium_supplementsMonitorModerateTheoreticalHypercalcemia risk; space doses.
  • MagnesiumSynergizeLowTheoreticalImmune support in HER2+ breast cancer.

Timing

References

Research

No published studies for Vitamin D₃ + K₂ yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Vitamin D₃ + K₂ depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 2000–5000 IU D3 + 100-200 mcg K2/day (po) QD with fatty meal; target 30-50 ng/mL 25(OH)D, Adjunct 4000 IU D3 + 180 mcg MK-7; monitor levels q3 months; Mg 300-400 mg co-supplement..

Trials studying Vitamin D₃ + K₂

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Appears in these protocol claims

Vitamin D₃ + K₂ is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar